Berobenatide

What is Berobenatide?

Berobenatide is the INN for Pfizer's investigational ultra-long-acting, fully-biased GLP-1 receptor agonist, previously known as PF-08653944 (PF'3944) and, in the Metsera era, MET-097 / MET-097i. The asset originated at Metsera and transferred to Pfizer when Pfizer completed its ~$10 billion acquisition of Metsera on November 13, 2025 after a bidding war with Novo Nordisk. "Fully-biased" means the molecule is engineered to selectively activate G-protein (cAMP) signaling at the GLP-1 receptor while minimizing β-arrestin recruitment — a design hypothesis that cleaner downstream signaling will improve tolerability and prolong efficacy by suppressing receptor internalization. Its defining clinical feature is dosing cadence: extended half-life supports once-monthly subcutaneous injection (0.5 mL volume) after an initial weekly titration phase, a departure from the weekly cadence that defines current approved GLP-1 therapy. The Phase 2b VESPER program (VESPER-1, -2, -3) delivered the data package presented at ADA 2026 — 15.9% non-placebo-adjusted weight loss at week 60 (VESPER-1 Part B, 2.4 mg weekly), HbA1c reduction of 2.2% at week 28 in T2D (VESPER-2, 1.6 mg weekly), and 12.3% placebo-adjusted weight loss at 28 weeks under monthly maintenance dosing (VESPER-3) — and Pfizer has now opened Phase 3 trials VESPER-4 through VESPER-6, with VESPER-6 (NCT07595549) the pivotal once-monthly obesity study currently recruiting. The company has stated ten Phase 3 trials planned for 2026 across chronic weight management, knee osteoarthritis, and obstructive sleep apnea, with first readouts in late 2027 and first approvals targeted 2028.

What Berobenatide Is Investigated For

Berobenatide (PF-08653944) is investigated primarily for obesity and chronic weight management, with the Phase 3 program also extending into type 2 diabetes (VESPER-5), all-monthly dosing in non-T2D obesity (VESPER-6, NCT07595549, pivotal), and additional indications including knee osteoarthritis and obstructive sleep apnea — Pfizer has stated a 10-trial Phase 3 program for 2026. The strongest current evidence is the Phase 2b VESPER package presented at ADA 2026: VESPER-1 Part B extended weight loss to 15.9% (non-placebo-adjusted) at week 60 on 2.4 mg weekly with no observed plateau; VESPER-2 in T2D delivered HbA1c -2.2% at week 28 (1.6 mg weekly) versus -0.2% placebo; and VESPER-3 showed 12.3% placebo-adjusted weight loss at 28 weeks using weekly titration followed by monthly maintenance, with continued weight loss through the cadence switch. The strategic claim is not effect-size superiority versus tirzepatide or retatrutide (weight-loss magnitude trails the top of the class) but cadence and tolerability — once-monthly maintenance with reportedly low GI adverse events and low discontinuation under rapid escalation. Honest caveats: no Phase 3 readouts yet, no peer-reviewed publication of the VESPER data (press-release and ADA-conference stage), no cardiovascular outcomes data, the "fully-biased GLP-1" tolerability hypothesis is pharmacologically interesting but not yet clinically validated in head-to-head studies, and first approvals are not expected before 2028.

How It Works

Berobenatide is a GLP-1 receptor agonist (like Ozempic and Wegovy) with two design twists: it's engineered to last long enough for once-monthly shots after initial titration, and it preferentially activates the insulin-releasing, appetite-suppressing arm of the GLP-1 receptor while dialing down the side-effect-associated arm. The hypothesis: similar efficacy, better tolerability, fewer injections.

Berobenatide is an acylated GLP-1 analog engineered for extended plasma half-life sufficient to support once-monthly dosing at maintenance. The molecular mechanism is canonical GLP-1 receptor agonism: binding to GLP-1R on pancreatic β-cells potentiates glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and reduces appetite via hindbrain and hypothalamic circuits. The distinguishing pharmacological feature is biased agonism — berobenatide preferentially stabilizes GLP-1R conformations favoring G-protein (Gαs/cAMP) signaling over β-arrestin-2 recruitment. In preclinical and early clinical pharmacology work, this biased signaling profile is hypothesized to preserve insulinotropic and appetite effects while reducing GI adverse events driven by β-arrestin-mediated receptor internalization and sustained GI tract activation. The Phase 2b VESPER program tested weekly titration (to minimize acute nausea) followed by transition to monthly maintenance; in VESPER-3, weight loss continued past the weekly-to-monthly cadence switch, supporting the monthly-dosing thesis pharmacokinetically. The 0.5 mL injection volume at the monthly maintenance dose is small enough to remain compatible with auto-injector device formats.

Evidence Snapshot

Forms & Administration

Investigational subcutaneous injection in a 0.5 mL volume compatible with auto-injector formats. Phase 2b VESPER-3 used weekly dosing with titration for 12 weeks followed by monthly maintenance dosing through week 28; the final 64-week assessment is pending. Phase 3 will test both weekly-then-monthly and all-monthly regimens (VESPER-6 is the pivotal all-monthly obesity study). Not available for general clinical or investigational use outside Pfizer's trial program.

Common Questions

Safety Profile